This is a prospective, longitudinal, descriptive study that will include adult participants infected and uninfected with Sars-CoV-2 at the time of recruitment.
Participants will be divided into 3 groups of 30 evaluable subjects:
* uninfected,
* asymptomatically infected,
* symptomatically infected.
The participants will be identified within the Ile-de-France medical analysis laboratories partners of the project.
Study with sample collection:
\- For participants infected with SARS-CoV-2: Inclusion visit V0, ≤ 3 days after PCR test Follow-up visit V1, 7 d ± 1 d after V0 Follow-up visit V2, 31 d ± 2 d after V0 V3 follow-up visit, 91 d ± 5 d after V0
\- For participants not infected with SARS-CoV-2 : Inclusion visit V0, ≤ 3 days after PCR test V1' visit, no more than 96 d after V0.
